JPWO2019198100A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019198100A5 JPWO2019198100A5 JP2020555387A JP2020555387A JPWO2019198100A5 JP WO2019198100 A5 JPWO2019198100 A5 JP WO2019198100A5 JP 2020555387 A JP2020555387 A JP 2020555387A JP 2020555387 A JP2020555387 A JP 2020555387A JP WO2019198100 A5 JPWO2019198100 A5 JP WO2019198100A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sugar
- preparation according
- preparation
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 125000000647 trehalose group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189255A JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013646 | 2018-04-10 | ||
| IN201841013646 | 2018-04-10 | ||
| PCT/IN2019/050292 WO2019198100A1 (en) | 2018-04-10 | 2019-04-10 | Antibody formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189255A Division JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521159A JP2021521159A (ja) | 2021-08-26 |
| JPWO2019198100A5 true JPWO2019198100A5 (https=) | 2022-04-15 |
| JP2021521159A5 JP2021521159A5 (https=) | 2022-04-15 |
Family
ID=68163986
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555387A Pending JP2021521159A (ja) | 2018-04-10 | 2019-04-10 | 抗体製剤 |
| JP2023189255A Active JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189255A Active JP7793581B2 (ja) | 2018-04-10 | 2023-11-06 | 抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12030948B2 (https=) |
| EP (1) | EP3773694A4 (https=) |
| JP (2) | JP2021521159A (https=) |
| CN (1) | CN112218654A (https=) |
| AU (1) | AU2019253070A1 (https=) |
| BR (1) | BR112020020707A2 (https=) |
| CO (1) | CO2020013552A2 (https=) |
| SG (1) | SG11202009874QA (https=) |
| WO (1) | WO2019198100A1 (https=) |
| ZA (1) | ZA202006263B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018007520A (es) | 2015-12-18 | 2018-08-01 | Astellas Pharma Inc | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. |
| AU2019251452A1 (en) * | 2018-04-10 | 2020-11-26 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| KR20230010239A (ko) * | 2020-05-11 | 2023-01-18 | 메디뮨 리미티드 | 항-il-33 항체의 제형물 |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| WO2022101935A1 (en) * | 2020-11-12 | 2022-05-19 | Dr. Reddy’S Laboratories Limited | Stable aqueous high concentration formulation of integrin antibody |
| US20240100158A1 (en) * | 2021-01-20 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Freeze dried antibody formulations and methods thereof |
| AU2022271025A1 (en) * | 2021-05-07 | 2023-12-14 | Dr. Reddy’S Laboratories Limited | A method of improving stability of an antibody formulation |
| US20240254237A1 (en) * | 2021-06-04 | 2024-08-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| KR20250120995A (ko) | 2022-11-07 | 2025-08-11 | 업스트림 바이오, 인크. | 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025041000A1 (en) * | 2023-08-21 | 2025-02-27 | Intas Pharmaceuticals Ltd. | STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358763C2 (ru) * | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| DK3311834T3 (da) * | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| WO2017015198A1 (en) * | 2015-07-17 | 2017-01-26 | Coherus Biosciences, Inc. | Stable aqeous formulations of natalizumab |
| US12582809B2 (en) * | 2018-01-26 | 2026-03-24 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor |
| WO2020104705A2 (en) * | 2018-11-23 | 2020-05-28 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
-
2019
- 2019-04-10 US US17/045,380 patent/US12030948B2/en active Active
- 2019-04-10 WO PCT/IN2019/050292 patent/WO2019198100A1/en not_active Ceased
- 2019-04-10 EP EP19784340.2A patent/EP3773694A4/en active Pending
- 2019-04-10 AU AU2019253070A patent/AU2019253070A1/en not_active Abandoned
- 2019-04-10 BR BR112020020707-1A patent/BR112020020707A2/pt unknown
- 2019-04-10 SG SG11202009874QA patent/SG11202009874QA/en unknown
- 2019-04-10 JP JP2020555387A patent/JP2021521159A/ja active Pending
- 2019-04-10 CN CN201980037792.0A patent/CN112218654A/zh active Pending
-
2020
- 2020-10-08 ZA ZA2020/06263A patent/ZA202006263B/en unknown
- 2020-10-28 CO CONC2020/0013552A patent/CO2020013552A2/es unknown
-
2023
- 2023-11-06 JP JP2023189255A patent/JP7793581B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521159A5 (https=) | ||
| JPWO2019198100A5 (https=) | ||
| JP7793581B2 (ja) | 抗体製剤 | |
| CN102712677B (zh) | 脂肽组合物和相关方法 | |
| TWI653048B (zh) | 含有肉毒桿菌毒素的穩定液體組合物 | |
| US8795686B2 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| AU2009289212B2 (en) | New protecting compositions for recombinantly produced factor VIII | |
| US6238664B1 (en) | Process for stabilizing proteins | |
| WO1992015331A1 (en) | Lyophilized monoclonal antibody preparation | |
| JP2010511665A5 (https=) | ||
| TW202535466A (zh) | 抗-il-23p19抗體調配物 | |
| JP2021521171A5 (https=) | ||
| US12491229B2 (en) | Stabilized peptide composition | |
| JP2021521168A5 (https=) | ||
| JPWO2019198101A5 (https=) | ||
| JP2708749B2 (ja) | 修飾型ｔＰＡ含有注射用組成物 | |
| US9907835B2 (en) | Stable Factor VIII formulations with low sugar-glycine | |
| JPWO2019198099A5 (https=) | ||
| RU2020136713A (ru) | Композиция из антител | |
| JPWO2022132636A5 (https=) | ||
| WO2022200811A1 (en) | Modified chimeric coronavirus spike protein for enhancement of viral titers | |
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK40033832A (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein |